Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Karuna Therapeutics Inc (KRTX) USD0.0001

Sell:$80.29 Buy:$80.55 Change: $4.37 (5.16%)
Market closed |  Prices as at close on 21 September 2020 | Switch to live prices |
Sell:$80.29
Buy:$80.55
Change: $4.37 (5.16%)
Market closed |  Prices as at close on 21 September 2020 | Switch to live prices |
Sell:$80.29
Buy:$80.55
Change: $4.37 (5.16%)
Market closed |  Prices as at close on 21 September 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Karuna Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to address disabling neuropsychiatric conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is developing a pipeline of therapeutic programs to address symptoms associated with schizophrenia and psychosis associated with Alzheimer’s disease (AD), as well as various forms of pain. KarXT is a combination of xanomeline and trospium.

Contact details

Address:
33 Arch St Ste 3110
BOSTON
02110-1424
United States
Telephone:
+1 (857) 4492244
Website:
https://karunatx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
KRTX
ISIN:
US48576A1007
Market cap:
$2.25 billion
Shares in issue:
26.62 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Steven Paul
    Chairman of the Board, President, Chief Executive Officer
  • Troy Ignelzi
    Chief Financial Officer
  • Andrew Miller
    Chief Operating Officer
  • Giorgio Attardo
    Vice President, CMC and Preclinical Development
  • Stephen Brannan
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.